Gemtesa 75 MG tablet 90S
Ended Awarded Last action
- Contract number
- SPE2DR26F9MZ9
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,273
Award facts
- Contract value 100% obligated
- $10,273.49 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $10,273.49 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 26, 2026, for the supply of Gemtesa 75 mg tablets (90-count units). This non-competitive delivery order will be performed in Conshohocken, Pennsylvania, with an ultimate completion date of January 27, 2026. The award represents a task order executed under AmerisourceBergen's parent company, Cencora, Inc., which holds a significant indefinite delivery contract (IDC) with DLA Troop Support Medical valued at up to $999,999,999 through December 31, 2031. This prime IDC vehicle enables Cencora to supply a comprehensive range of pharmaceutical products and medical commodities to support military healthcare programs globally, including specialty medications, brand-name and generic drugs, and vaccines across multiple therapeutic domains.
AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems through the DLA Medical Supply Chain. As the operating subsidiary of Cencora, Inc., the company has demonstrated capability to efficiently fulfill government contracts for essential pharmaceutical commodities required by military treatment facilities and federal medical institutions. The delivery of Gemtesa, a medication for bladder conditions, exemplifies the company's role in supplying specialized prescription medications to support the healthcare needs of the Department of Defense and its beneficiaries.
Quick answers
Who was awarded contract SPE2DR26F9MZ9?
SPE2DR26F9MZ9 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 26, 2026.
How much is contract SPE2DR26F9MZ9 worth?
The government has obligated $10,273 on SPE2DR26F9MZ9.
Is contract SPE2DR26F9MZ9 an order under another contract?
Yes. SPE2DR26F9MZ9 is a delivery order under SPE2DR25D2206, an indefinite delivery contract.
Was contract SPE2DR26F9MZ9 competed?
The extent of competition for SPE2DR26F9MZ9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award